JAKPOT T1D is a study for those newly diagnosed with T1D. The background of the image is blue with bursts of color in the lower left side.
Research Spotlight
Read more
New onset study now open for enrollment — TrialNet launches study to test JAK inhibitors in type 1 diabetes
TrialNet researchers are testing two promising new treatments to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).
Raised hands appear from the bottom of the image with the text "HELP US STOP-T1D". The background of the image is pale green and contains Y-shaped autoantibodies arranged into the shape of a stop sign.
Research Spotlight
Read more
New prevention study now open for enrollment – Help us find out if a low dose immunotherapy can STOP-T1D
TrialNet researchers are testing low-dose anti-thymocyte globulin (ATG), an immunotherapy, to find out if it can delay or prevent type 1 diabetes (T1D) in people at high risk of clinical diagnosis (Stage 3) within two years.
DECA Executive Director Terry posing for a photo with family members on a dock: wife, daughter, son-in-law, grandchild, and dog
Media Release
Read more
Diabetes camps provide summer fun and independence
DECA Executive Director Terry Ackley, and his wife, Carol, volunteered at Camp Seale Harris for several years before he was hired as the Camp’s executive director in 1995. He served in that role until joining DECA in 2012. Pictured here: Terry and Carol (right) with daughter, Emily (left), son-in-law, Patrick, and granddaughter, Vivienne.
Sign up here to join our mailing list for the latest updates on important T1D research and events, straight to your inbox. You can also find us on Facebook @DiabetesTrialNet.
